Morphology of vascular, renal, and heart lesions in the antiphospholipid syndrome: Relationship to pathogenesis

被引:18
作者
Amigo M.-C. [1 ]
García-Torres R. [1 ]
机构
[1] Department of Rheumatology, Instituto Nacional de Cardiologìa Ignacio Chàvez, Juan Badiano # 1, Tlalpan, Mèxico, Distrito Federal
关键词
Heart Lesion; Lupus Anticoagulant; Renal Vein Thrombosis; Rheumatol; Systemic Lupus Erythematosus;
D O I
10.1007/s11926-000-0089-4
中图分类号
学科分类号
摘要
A growing body of evidence suggests that aPL are not only serological markers of the antiphospholipid syndrome (APS), but may also directly contribute to the development of thrombosis and other manifestations, including the APS vasculopathy. The latter has been documented in leptmeninges, lung, skin, myocardium, peripheral arteries, and kidney. Renal lesions, a common feature of primary antiphospholipid syndrome (PAPS), include occlusion of principal renal arteries or their main branches, TMA, cortical ischemia, and renal vein thrombosis. Within the cardiac manifestations associated with aPL, valvular involvement is the most common. Histologic findings in valve specimens are consistent with a noninflammatory lesion characterized by intravalvular capillary thrombosis, laminar or verrucous superficial thrombosis, vascular proliferation, fibrosis, and calcification. Even though there is general consensus that endothelial damage triggers the chain of events that results in valve thickening, fusion, rigidity, and ultimately functional abnormalities, we believe that more experimental work remains to be done on the initial valve insult in APS. © 2000, Current Science Inc.
引用
收藏
页码:262 / 270
页数:8
相关论文
共 60 条
[41]  
Mondragon-Ramirez G., Bochicchio T., Garcia-Torres R., Et al., Recurrent renal thrombotic angiopathy after kidney transplantation in two patients with primary antiphospholipid syndrome (PAPS), Clin Transplant, 8, pp. 93-96, (1994)
[42]  
Vaidya S., Wang C.C., Gugliuzza C., Et al., Relative risk of posttransplant renal thrombosis in patients with antiphospholipid antibodies, Clin Transplant, 12, pp. 439-444, (1998)
[43]  
Hughes G.R.V., Harris N.N., Gharavi A.E., The anticardiolipin syndrome, J Rheumatol, 13, pp. 486-489, (1986)
[44]  
Kattwinkel N., Villanueva A.G., Labib S.B., Et al., Myocardial infarction caused by cardiac microvasculopathy in a patient with the primary antiphospholipid syndrome, Ann Intern Med, 116, pp. 974-976, (1992)
[45]  
Ford P.M., Ford S.E., Lillicrap D.P., Association of lupus anticoagulant with severe valvular heart disease in systemic lupus erythematosus, J Rheumatol, 15, pp. 597-600, (1988)
[46]  
Lubbe W.F., Asherson R.A., Intracardiac thrombus in systemic lupus erythematosus associated with lupus anticoagulant, Arthritis Rheum, 31, pp. 1453-1454, (1988)
[47]  
Khamashta M.A., Cervera R., Asherson R.A., Et al., Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus, Lancet, 335, pp. 1541-1544, (1990)
[48]  
Cervera R., Khamashta M.A., Font J., Et al., High prevalence of significant heart valve lesions in patients with the “primary” antiphospholipid syndrome, Lupus, 1, pp. 43-47, (1991)
[49]  
Garcia-Torres R., Amigo M.C., De la Rosa A., Et al., Valvular heart disease in primary antiphospholipid syndrome (PAPS): clinical and morphological findings, Lupus, 5, pp. 56-61, (1996)
[50]  
Ford S.E., Charrette E.J.P., Knight J., Et al., A possible role for antiphospholipid antibodies in acquired cardiac valve deformity, J Rheumatol, 17, pp. 1499-1503, (1990)